{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:57:56Z","timestamp":1780394276589,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>T\u00a0cell-mediated eosinophilia is associated with numerous conditions\u2014including atopic dermatitis, food allergies, and asthma\u2014collectively known as the \u201catopic march.\u201d Benralizumab is a recombinant, humanized, afucosylated monoclonal antibody directed against the \u237a\u00a0chain of the eosinophil cell surface receptor IL-5R. Benralizumab treatment causes near-complete depletion of circulating eosinophils and was approved in 2017 for add-on, maintenance treatment of severe asthma with an eosinophilic phenotype, based on the results of the CALIMA and SIROCCO pivotal trials. Benralizumab is not currently approved for the treatment of eosinophilic conditions besides asthma; however, during the CALIMA trial, spontaneous resolution of atopic dermatitis was observed in a patient, concurrent with reduction in her asthma symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In January 2015, a 14-year-old Asian girl with severe, uncontrolled asthma was enrolled in CALIMA. The patient\u2019s baseline eosinophil blood count was 1200\u00a0cells\/\u03bcL, her pre-bronchodilator forced expiratory volume in 1\u00a0second (FEV<jats:sub>1<\/jats:sub>) was 1.9\u00a0L and FEV<jats:sub>1<\/jats:sub>\/forced vital capacity (FVC) ratio was 71.4%, and her post-bronchodilator FEV<jats:sub>1<\/jats:sub> was 3.2\u00a0L (FEV<jats:sub>1<\/jats:sub>\/FVC of 115.9%). Her overall baseline asthma symptom score was 3.9 and her asthma exacerbation rate in the prior year was 4. She also displayed a pronounced, pruritic, chronic, inflammatory rash consistent with atopic dermatitis across her face. The investigator was blinded to the patient\u2019s treatment group during treatment; however, her asthma symptoms diminished over the course of the study (FEV<jats:sub>1<\/jats:sub> at 56\u00a0weeks, 3.01\u00a0L\/110.5% (pre) and 3.25\u00a0L\/119.3% (post); overall asthma symptom score 2.1; one influenza-associated exacerbation). Furthermore, her atopic dermatitis symptoms resolved spontaneously within the first 5\u00a0months of the study. After unblinding, the patient was confirmed to have been randomized to an active treatment arm, and her blood eosinophil count had dropped below the limit of detection after the first study dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Given the potential shared mechanisms between eosinophilic asthma and atopic dermatitis, it is plausible that benralizumab-induced eosinopenia factored into the resolution of the patient\u2019s atopic dermatitis. Further clinical studies are warranted to determine whether benralizumab or other drugs targeted against IL-5\/IL-5R may be useful in managing multiple conditions associated with eosinophilia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02663-2","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:21:50Z","timestamp":1614990110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"David N.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"key":"2663_CR1","first-page":"590","volume":"101","author":"W Frazier","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101:590\u20138.","journal-title":"Am Fam Physician"},{"key":"2663_CR2","first-page":"52","volume":"14","author":"S Kapur","year":"2018","unstructured":"Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy asthma. Clin Immunol. 2018;14:52.","journal-title":"Clin Immunol"},{"key":"2663_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.anai.2017.10.037","volume":"120","author":"DA Hill","year":"2018","unstructured":"Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120:131\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2663_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2500\/aap.2019.40.4277","volume":"40","author":"SE Chiarella","year":"2019","unstructured":"Chiarella SE. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria. Allergy Asthma Proc. 2019;40:485\u20139.","journal-title":"Allergy Asthma Proc"},{"key":"2663_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/ACI.0000000000000336","volume":"17","author":"TR Patel","year":"2017","unstructured":"Patel TR, Sur S. IgE and eosinophils as therapeutic targets in asthma. Curr Opin Allergy Clin Immunol. 2017;17:42\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2663_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11882-012-0290-3","volume":"12","author":"ZJ Amini-Vaughan","year":"2012","unstructured":"Amini-Vaughan ZJ, Martinez-Moczygemba M, Huston DP. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer. Curr Allergy Asthma Rep. 2012;12:402\u201312.","journal-title":"Curr Allergy Asthma Rep"},{"key":"2663_CR7","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128\u201341.","journal-title":"Lancet"},{"key":"2663_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/bjd.17766","volume":"181","author":"AD Irvine","year":"2019","unstructured":"Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner\u2019s guide. Br J Dermatol. 2019;181:895\u2013906.","journal-title":"Br J Dermatol"},{"issue":"1344\u20131353","key":"2663_CR9","first-page":"e2","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(1344\u20131353):e2.","journal-title":"J Allergy Clin Immunol"},{"key":"2663_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/JAA.S78049","volume":"9","author":"LD Tan","year":"2016","unstructured":"Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71\u201381.","journal-title":"J Asthma Allergy"},{"key":"2663_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","volume":"111","author":"TH Pham","year":"2016","unstructured":"Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21\u20139.","journal-title":"Respir Med"},{"key":"2663_CR12","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115\u201327.","journal-title":"Lancet"},{"key":"2663_CR13","unstructured":"Fasenra prescribing information. https:\/\/www.azpicentral.com\/fasenra\/fasenra.pdf. 2019. Accessed 27 July 2019."},{"key":"2663_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46\u201359.","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02663-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-021-02663-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02663-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T01:03:12Z","timestamp":1614992592000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02663-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02663-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient\u2019s legal guardian gave informed consent for the patient to participate in the CALIMA clinical trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and her legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DNP declares that he has no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}